These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 28012683)

  • 1. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
    Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
    Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.
    Cojutti P; Sartor A; Righi E; Scarparo C; Bassetti M; Pea F
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
    Del Bono V; Giacobbe DR; Marchese A; Parisini A; Fucile C; Coppo E; Marini V; Arena A; Molin A; Martelli A; Gratarola A; Viscoli C; Pelosi P; Mattioli F
    Virulence; 2017 Jan; 8(1):66-73. PubMed ID: 27430122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae.
    Gaibani P; Lombardo D; Bartoletti M; Ambretti S; Campoli C; Giannella M; Tedeschi S; Conti M; Mancini R; Landini MP; Re MC; Viale P; Lewis RE
    Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1925-1931. PubMed ID: 31278562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in a case series of orthotopic liver transplant recipients.
    Gatti M; Rinaldi M; Laici C; Ambretti S; Siniscalchi A; Viale P; Pea F
    J Antimicrob Chemother; 2024 Oct; 79(10):2586-2590. PubMed ID: 39087356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
    Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of tigecycline alone or in combination for experimental infections by KPC carbapenemase-producing Klebsiella pneumoniae.
    Fergadaki S; Renieris G; Machairas N; Sabracos L; Droggiti DI; Misiakos E; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2021 Sep; 58(3):106384. PubMed ID: 34161789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?
    Cojutti P; Sartor A; Bassetti M; Scarparo C; Pea F
    J Glob Antimicrob Resist; 2018 Sep; 14():238-241. PubMed ID: 29775786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.
    Tumbarello M; Trecarichi EM; De Rosa FG; Giannella M; Giacobbe DR; Bassetti M; Losito AR; Bartoletti M; Del Bono V; Corcione S; Maiuro G; Tedeschi S; Celani L; Cardellino CS; Spanu T; Marchese A; Ambretti S; Cauda R; Viscoli C; Viale P;
    J Antimicrob Chemother; 2015 Jul; 70(7):2133-43. PubMed ID: 25900159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Short Versus Prolonged Infusion of Standard Dose of Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae Isolates in Different Patient Groups: A Pharmacokinetic-Pharmacodynamic Approach.
    Vourli S; Tsala M; Kotsakis S; Daikos GL; Tzouvelekis L; Miriagou V; Zerva L; Meletiadis J
    J Pharm Sci; 2016 Apr; 105(4):1513-8. PubMed ID: 27019965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of meropenem by continuous infusion to treat a patient with a Bla(kpc-2)-positive Klebsiella pneumoniae blood stream infection.
    Ho VP; Jenkins SG; Afaneh CI; Turbendian HK; Nicolau DP; Barie PS
    Surg Infect (Larchmt); 2011 Aug; 12(4):325-7. PubMed ID: 21859337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic modelling of meropenem against VIM-producing Klebsiella pneumoniae isolates: clinical implications.
    Tsala M; Vourli S; Kotsakis S; Daikos GL; Tzouvelekis L; Zerva L; Miriagou V; Meletiadis J
    J Med Microbiol; 2016 Mar; 65(3):211-218. PubMed ID: 26697851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.
    Wiskirchen DE; Koomanachai P; Nicasio AM; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1420-7. PubMed ID: 21282442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates.
    Gaibani P; Lombardo D; Lewis RE; Mercuri M; Bonora S; Landini MP; Ambretti S
    J Antimicrob Chemother; 2014 Jul; 69(7):1856-65. PubMed ID: 24648503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation.
    Wang G; Yu W; Cui Y; Shi Q; Huang C; Xiao Y
    BMC Infect Dis; 2021 Mar; 21(1):307. PubMed ID: 33771113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
    Bulik CC; Christensen H; Li P; Sutherland CA; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2010 Feb; 54(2):804-10. PubMed ID: 19995927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
    Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
    J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
    Pai MP; Cojutti P; Pea F
    Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
    Gaibani P; Lewis RE; Volpe SL; Giannella M; Campoli C; Landini MP; Viale P; Re MC; Ambretti S
    Int J Infect Dis; 2017 Dec; 65():1-3. PubMed ID: 28951106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.